Insider Trading at Neurocrine Biosciences?

Lloyd Doyle
January 23, 2018

Insiders have sold 121,780 shares of company stock worth $9,012,926 in the last quarter. Lastly, more shares traded means less of a spread in between the bid and the ask, which can effect your bottom line. It is down 0.00% since January 22, 2017 and is. It has underperformed by 4.19% the S&P500. During the same quarter last year, the company posted ($0.43) earnings per share. equities research analysts anticipate that Neurocrine Biosciences will post -1.61 earnings per share for the current fiscal year. (NASDAQ:INGN). State Street holds 0% or 423,989 shares. Moreover, Susquehanna Intll Limited Liability Partnership has 0% invested in Neurocrine Biosciences, Inc. OBrien Christopher Flint sold $422,702 worth of stock or 6,925 shares. NVR, Inc. (NYSE:NVR) has risen 38.86% since January 23, 2017 and is uptrending. It has underperformed by 4.19% the S&P500. Bank of Montreal Can now owns 10,767 shares of the company's stock worth $835,000 after purchasing an additional 8,837 shares in the last quarter. The company has market cap of $1.39 billion. The firm offers men's and women's sportswear and related products under the Tommy Bahama brand; and women's and girl's dresses and sportswear, scarves, bags, jewelry, and belts, as well as footwear and children's apparel under the Lilly Pulitzer brand. It has a 25.3 P/E ratio. It also provides branded and private label men's apparel, including tailored clothing, casual trousers, and sportswear, as well as apparel under licensed brands, such as the Kenneth Cole, Dockers, Geoffrey Beene, Nick Graham, and Andrew Fezza. BMO Capital Markets maintained it with "Buy" rating and $109.0 target in Wednesday, November 1 report. Therefore 92% are positive. When looking at Neurocrine Biosciences, Inc., it is crucial to find out the sector and industry it belongs too, which is respectively Healthcare, and Drugs - Generic. The current ratio for NBIX is 14.40 and that of JONE is 0.60. The company was maintained on Friday, October 20 by Wells Fargo. The stock has a market capitalization of $7,139.61, a PE ratio of -36.34, a P/E/G ratio of 75.47 and a beta of 0.35. The rating was downgraded by DA Davidson on Friday, September 8 to "Hold". The firm has "Hold" rating by Zelman given on Monday, May 29. Piper Jaffray has "Buy" rating and $96.0 target. The company was maintained on Thursday, September 1 by Telsey Advisory. (NYSE:OXM) on Tuesday, January 9 with "Buy" rating. Needham & Company LLC reissued a "buy" rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd.

Investors sentiment increased to 1.66 in 2017 Q3. Its up 0.41, from 1.25 in 2017Q2. Dividends are paid out to investors from the free cash flow that the company has. Aberdeen Indonesia Fund, Inc. Jennison Associate Ltd Company, a New York-based fund reported 321,145 shares. Sivik Glob Healthcare Ltd has 30,000 shares for 0.63% of their portfolio. The number of shares now owned by investors are 88.33 mln. $3.04 million worth of Neurocrine Biosciences, Inc. J&P China Capital Management Company who had been investing in Facebook Inc for a number of months, seems to be bullish on the $526.79 billion market cap company. It was reported on Jan, 22 by (NASDAQ:NBIX). Tocqueville Asset Mngmt Lp invested 0.01% in Neurocrine Biosciences, Inc. Bamco Incorporated Ny invested 0.01% of its portfolio in Inogen, Inc. (NYSE:OXM). 215,219 were reported by Bancorporation Of America Corp De. Lord Abbett Lc owns 317,341 shares. First Citizens Bankshares And Trust has invested 0.13% in NVR, Inc.

Since January 10, 2018, it had 0 buys, and 1 sale for $381,197 activity. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Neurocrine Biosci had 41 analyst reports since August 18, 2015 according to SRatingsIntel. Palo Capital invested 1.47% of its portfolio in NVR, Inc. (NASDAQ:NBIX) earned "Buy" rating by Cowen & Co on Friday, October 27. The company was maintained on Wednesday, November 22 by Robert W. Baird. Needham & Company LLC now has a buy rating on the stock. NVR has $3750.0 highest and $1400 lowest target.

Neurocrine Biosciences (NASDAQ NBIX) traded up $2.12 during midday trading on Tuesday, reaching $80.68. The firm earned "Buy" rating on Thursday, September 7 by Oppenheimer. (NASDAQ:NBIX). Price T Rowe Assocs Md owns 7.21M shares. On Tuesday, October 3 the stock rating was upgraded by Jefferies to "Buy".

The analyst recommendations from a month ago are 4 Buy, 0 Overweight, 0 Sell, 3 Hold and 0 Underweight. Lippoldt Darin sold $6,000 worth of stock. Finally, Leerink Swann reissued an "outperform" rating and issued a $83.00 price objective (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. The ROI of NBIX is -46.80% while that of JONE is 1.60%. "(NBIX) Insider Sells $128,570.00 in Stock" was reported by BBNS and is owned by of BBNS. Accern also assigned news coverage about the company an impact score of 45.9604646665802 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Other reports by Iphone Fresh

Discuss This Article